3-Acetoxy-2-(acetoxymethyl)-1-propanol | 138435-86-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Acetoxy-2-(acetoxymethyl)-1-propanol
• 英文别名: [2-(acetoxymethyl)-3-hydroxypropyl] acetate；[2-(Acetyloxymethyl)-3-hydroxypropyl] acetate
• CAS: 138435-86-6
• 化学式: C₈H₁₄O₅
• 分子量: 190.196
• InChiKey: GMFFYZCHSYHKLM-UHFFFAOYSA-N

物化性质

• 沸点：
  229.7±20.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-Acetoxy-2-(acetoxymethyl)-1-propanol 以79的产率得到[2-(Acetyloxymethyl)-3-methylsulfonyloxypropyl] acetate
  参考文献：
  名称：

  [EN] PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS
  [FR] ACYCLONUCLEOSIDES DE PURINE UTILISES COMME AGENTS ANTIVIRAUX

  摘要：

  本发明涉及使用式（1）的化合物在乙型肝炎病毒感染的治疗和/或预防中的应用，其中： R1代表氢、卤素、羟基、叠氮基、烷氧基、芳基氧基、硫基、烷硫基、氨基、烷基氨基、肼基、羟胺基、苄氧基、NRR'或NRCOR'; R2代表氢、卤素、羟基、叠氮基、烷氧基、芳基氧基、硫基、烷硫基、氨基、烷基氨基、肼基、羟胺基、苄氧基、NRR'或NRCOR'; R和R'独立地选择自氢、烷基和芳基；或其盐和药学上可接受的衍生物。

  公开号：

  WO1999012927A1
• 作为产物：
  描述：

  1,3-Diacetoxy-2-(acetoxymethyl)propane 在 sodium hydroxide 作用下， 反应 5.0h， 生成 3-Acetoxy-2-(acetoxymethyl)-1-propanol
  参考文献：
  名称：

  Chemoenzymic preparation of asymmetrized tris(hydroxymethyl)methane (THYM*) and of asymmetrized bis(hydroxymethyl)acetaldehyde (BHYMA*) as new highly versatile chiral building blocks

  摘要：

  A series of asymmetrized tris(hydroxymethyl)methanes 2 and bis(hydroxymethyl)acetaldehydes 3 have been prepared in both enantiomeric forms through a chemoenzymatic methodology. The key step is the highly enantioselective PPL-catalyzed monohydrolysis of 2(E)-alkenyl-1,3-diacetoxypropanes 25-27. A careful study on the effect of unsaturations adjacent to the prochiral center in a series of 2-substituted 1,3-diacetoxypropanes has confirmed the suggested beneficial effect of a pi-system in that position but has also unveiled an unprecedented dramatic effect of double-bond configuration on enantioselectivity. A new empirical model for the interpretation of these and other results, based both on polarity and steric arguments, is proposed. This study provides a general protocol for the efficient synthesis of asymmetrized 1,3-propanediols bearing in position 2 saturated or unsaturated carbon chains.

  DOI：

  10.1021/jo00031a039

文献信息

• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：AZURA OPHTHALMICS LTD

  公开号：WO2020212755A1

  公开（公告）日：2020-10-22

  Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti- inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

  本文描述了用于治疗眼表面疾病的组合物和方法，包括睑板腺功能障碍、睑缘炎、干眼症和其他眼前表面的炎症和/或感染性疾病。所述组合物和方法包括表现出角质溶解活性的角质溶解共轭物，以及抗炎或其他理想活性。将所述组合物局部施用于眼睑边缘或周围区域可为患有眼表面疾病的患者提供治疗益处。
• [EN] LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS<br/>[FR] LIPIDES ET COMPOSITIONS LIPIDIQUES POUR LE LARGAGE D'AGENTS ACTIFS
  申请人：NOVARTIS AG

  公开号：WO2015095340A1

  公开（公告）日：2015-06-25

  This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

  该发明提供了化合物的结构式（I）：或其药用可接受盐，其中R1-R4、n和p在此处定义。结构式（I）的化合物及其药用可接受盐是用于将生物活性剂传递至细胞和组织中的阳离子脂质。
• Compounds and methods for the treatment of ocular disorders
  申请人：Azura Ophthalmics Ltd.

  公开号：US10875845B2

  公开（公告）日：2020-12-29

  Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

  本文描述了用于治疗眼表疾病的组合物和方法，包括睑板腺功能障碍、睑缘炎、干眼症和其他眼前表面炎症和/或感染性疾病。所述组合物和方法包括具有角质溶解活性、抗炎或其他理想活性的角质溶解共轭物。对眼睑边缘或周围区域局部施用所述组合物可为眼表疾病患者带来治疗益处。
• COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Azura Ophthalmics Ltd.

  公开号：EP3955926A1

  公开（公告）日：2022-02-23
• [EN] FUSED HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONDENSÉ
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2010027236A2

  公开（公告）日：2010-03-11

  The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.